Overview
Zhixiong Li practices practicing medicine in Hannover, Germany.
Their clinical expertise encompasses Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Acute Myeloid Leukemia (AML), and Leukemia.
They are actively involved in clinical research, co-authoring 21 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Zhixiong Li
Is Zhixiong Li a top-rated expert for Mast Cell Activation Syndrome (MCAS)?
MediFind is an objective health platform that identifies experts based on real-world data. Zhixiong Li is classified as an Experienced expert for Mast Cell Activation Syndrome (MCAS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Zhixiong Li participate in research or clinical trials?
Yes. Zhixiong Li has published 21 articles and abstracts on conditions like Mast Cell Activation Syndrome (MCAS). You can view a list of Zhixiong Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute Myeloid Leukemia (AML)
- LeukemiaLi isExperienced. Learn about Leukemia.
- Mast Cell Activation Syndrome (MCAS)
- Systemic MastocytosisLi isExperienced. Learn about Systemic Mastocytosis.